“…For example, the CNV gains at 1p11.2 (Jiang et al, 2011 ), 11q21 (Kazantseva et al, 2016 ), 16q11.2 (Savelyeva et al, 1994 ), and 17q11.1 are associated with breast cancer and are detected by each method, which is described in Figure 9 . Those at 14q11.2 (Kawasaki et al, 2007 ) and 16p11.2 (Weiss et al, 2008 ) are respectively related to lung cancer and autism, that at 10q11.21 (Rees et al, 2016 ) is associated with schizophrenia, those at 1q21 (Grzasko et al, 2012 ) and 2q12.3 (Erickson et al, 2014 ) are associated with multiple myeloma, and those at 14q11.1 (Thean et al, 2018 ) and 18q21.1 (Druliner et al, 2018 ) are associated with colorectal cancer. CNV loss at 20q13.2 (Hidaka et al, 2000 ) is associated with colorectal cancer, that at 14q32.33 (Ledet et al, 2013 ) is associated with prostate cancer, that at 4q13.2 (Yang et al, 2008 ) is associated with osteoporosis, and that at 3q29 (Biamino et al, 2016 ) is related to autism.…”